
Experience
Bridge to Life Sells Certain Assets to TransMedics
August 3, 2023
Cooley advised Bridge to Life, an organ preservation and perfusion technologies supplier, on its sale of certain assets – including its EVOSS heart and lung and LifeCradle heart perfusion assets – to TransMedics.
Related contacts
Related Practices & Industries
Thirty Madison Acquires Assets From The Pill Club in Section 363 Sale
June 20, 2023
Cooley advised Thirty Madison, a family of specialized healthcare brands, in its acquisition of certain assets from The Pill Club, following a sale process conducted by The Pill Club under Section 363 of the US Bankruptcy Code.
Related contacts
Related Practices & Industries
ACELYRIN Announces Pricing of Upsized Initial Public Offering
May 15, 2023
Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.
Related contacts
Related Practices & Industries
Absolute Software Announces $870 Million Acquisition by Crosspoint Capital
May 15, 2023
Cooley advised Absolute Software, a data risk management solutions and endpoint security provider, on its acquisition by Crosspoint Capital for approximately $870 million, inclusive of debt.
Related contacts
Related Practices & Industries
Amryt Pharma to Sell to Chiesi Farmaceutici in $1.48 Billion Cross-Border Transaction
January 9, 2023
Cooley advised Amryt Pharma, a Dublin, Ireland-based commercial-stage biopharmaceutical company, on its definitive agreement to be acquired by Chiesi Farmaceutici, a Parma, Italy-based research-focused biopharmaceuticals and healthcare group, in a $1.48 billion cash and contingent value right (CVR) transaction. Partners Bill Sorabella, Claire Keast-Butler and Bill Roegge led the joint US and UK Cooley team advising Amryt.